Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
暂无分享,去创建一个
Avraham Eisbruch | A. Eisbruch | C. Pan | M. Schipper | C. Murdoch-Kinch | Amichay Meirovitz | A. Meirovitz | Charlie Pan | Carol Anne Murdoch-Kinch | Mathew Schipper
[1] J. Rieke,et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Levendag,et al. Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] A Ralph Henderson,et al. The bootstrap: a technique for data-driven statistics. Using computer-intensive analyses to explore experimental data. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[4] K. Chao,et al. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. , 2003, Seminars in oncology.
[5] A. Rademaker,et al. Effects of xerostomia on perception and performance of swallow function , 2001, Head & neck.
[6] M. Martel,et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. , 1998, International journal of radiation oncology, biology, physics.
[7] C. Terhaard,et al. A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: implications for future trials. , 2005, International journal of radiation oncology, biology, physics.
[8] R. Haddad,et al. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. , 2003, Seminars in oncology.
[9] C. Leemans,et al. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] E. Pow,et al. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma , 2003, Clinical Oral Investigations.
[11] D. Brizel,et al. How should we measure and report radiotherapy-induced xerostomia? , 2003, Seminars in radiation oncology.
[12] P. Fox,et al. Subjective reports of xerostomia and objective measures of salivary gland performance. , 1987, Journal of the American Dental Association.
[13] J. Dempsey,et al. Late Xerostomia After Intensity-Modulated Radiation Therapy Versus Conventional Radiotherapy , 2005, American journal of clinical oncology.
[14] S. Nill,et al. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. , 2004, International journal of radiation oncology, biology, physics.
[15] P. Haddad,et al. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] J. Roh,et al. Xerostomia following radiotherapy of the head and neck affects vocal function. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] LENT SOMA tables. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[18] D. Brizel,et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. , 2005, International journal of radiation oncology, biology, physics.
[19] B. Vikram,et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Büntzel,et al. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. , 2002, Seminars in radiation oncology.
[21] B. Ferguson. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer , 1994 .
[22] R K Ten Haken,et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.
[23] E. B. Butler,et al. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. , 2003, International journal of radiation oncology, biology, physics.
[24] B. Rhein,et al. Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] A. Hinke,et al. Randomized Phase III Trial of Postoperative Radiochemotherapy ± Amifostine in Head and Neck Cancer , 2003, Strahlentherapie und Onkologie.
[26] G. Lockwood,et al. A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.
[27] R. Henriksson,et al. Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. , 1992, European journal of cancer.
[28] P. Levendag,et al. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. , 2002, Seminars in oncology.
[29] M. Puglisi,et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.
[30] F. Fang,et al. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy , 2004, Cancer.
[31] L. Dawson,et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.
[32] Joseph O Deasy,et al. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. , 2005, International journal of radiation oncology, biology, physics.
[33] C. N. Coleman,et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.
[34] P. Lambin,et al. Preservation of parotid function with uncomplicated conformal radiotherapy. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[35] C. Tsien,et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. , 2005, International journal of radiation oncology, biology, physics.
[36] Joseph O Deasy,et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. , 2004, International journal of radiation oncology, biology, physics.
[37] Margie Hunt,et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience. , 2006, International journal of radiation oncology, biology, physics.
[38] G. Lockwood,et al. Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. , 2005, International journal of radiation oncology, biology, physics.
[39] P. Anné. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. , 2002, Seminars in oncology.
[40] E. B. Butler,et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. , 2004, International journal of radiation oncology, biology, physics.
[41] P. Xia,et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.
[42] G. Calais,et al. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. , 2002, Seminars in oncology.
[43] L. Dawson,et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. , 2003, International journal of radiation oncology, biology, physics.
[44] D. Robinson,et al. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[45] Yasumasa Nishimura,et al. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT. , 2005, Japanese journal of clinical oncology.
[46] T. Whelan,et al. A Phase I-II study in the use of acupuncture-like transcutaneous nerve stimulation in the treatment of radiation-induced xerostomia in head-and-neck cancer patients treated with radical radiotherapy. , 2003, International journal of radiation oncology, biology, physics.
[47] Heikki Joensuu,et al. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[48] D. Brizel,et al. The prevention and treatment of radiotherapy - induced xerostomia. , 2003, Seminars in radiation oncology.
[49] A. Monnier,et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. , 2006, International journal of radiation oncology, biology, physics.
[50] T. Pajak,et al. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.
[51] J. Schulte‐Mönting,et al. Different Saliva Substitutes for Treatment of Xerostomia Following Radiotherapy , 2005, Strahlentherapie und Onkologie.
[52] C. Perez,et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[53] Yaoh-Shiang Lin,et al. Parotid gland-sparing 3-dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: a dosimetric and clinical comparison with conventional radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[54] S. Leung,et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. , 2004, International journal of radiation oncology, biology, physics.
[55] Fabrice Denis,et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. , 2003, International journal of radiation oncology, biology, physics.
[56] P. Xia,et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. , 2000, International journal of radiation oncology, biology, physics.
[57] P. Levendag,et al. Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long‐term survivors , 2002, Head & neck.
[58] J. Deasy,et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. , 2001, International journal of radiation oncology, biology, physics.
[59] P. Xia,et al. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. , 2003, International journal of radiation oncology, biology, physics.
[60] Radhe Mohan,et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results. , 2004, International journal of radiation oncology, biology, physics.
[61] A. Hinke,et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? , 2003, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[62] G. Field,et al. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.
[63] E. B. Butler,et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. , 1999, International journal of radiation oncology, biology, physics.
[64] Robert L. White,et al. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09. , 2003, International journal of radiation oncology, biology, physics.
[65] D L McShan,et al. Is uniform target dose possible in IMRT plans in the head and neck? , 2002, International journal of radiation oncology, biology, physics.